Selecting Escitalopram versus Sertraline for Adult Major Depressive Disorder and Generalized Anxiety Disorder

1. Guideline‑Based Preference Based on Adverse‑Effect Profiles

The American College of Physicians recommends choosing a second‑generation antidepressant primarily according to its adverse‑effect profile rather than modest efficacy differences, because efficacy differences among agents are small. [1][2]3

Sertraline is linked to a higher incidence of diarrhea compared with other SSRIs, including escitalopram, making it less suitable for patients with a history of gastrointestinal upset. 2
Both escitalopram and sertraline carry the FDA black‑box warning for increased risk of suicidal thoughts and behaviors; close monitoring is required during the first 1–2 weeks after initiation. [1][3]
Sertraline has a greater propensity to cause discontinuation‑syndrome symptoms than many other SSRIs, although this risk is lower than that of paroxetine. [4][5]

Escitalopram exhibits minimal inhibition of CYP450 isoenzymes, resulting in a lower likelihood of clinically significant drug‑drug interactions compared with other SSRIs. [4][5]
Sertraline is metabolized by CYP2D6 and can interact with other medications that use this pathway, which is an important consideration in polypharmacy. [4][5]

When patients are on multiple CYP450‑metabolized drugs, prefer escitalopram because of its minimal interaction profile. [4][5]

For patients with a history of diarrhea or irritable bowel syndrome, avoid sertraline and consider escitalopram. 2

Escitalopram offers a simple fixed dose (10 mg daily, titratable to 20 mg), which is advantageous for patients concerned about adherence. (no citation needed)
Sertraline requires titration (starting 50 mg daily, increasing by 50 mg weekly to typical therapeutic ranges of 100–200 mg), suitable for patients who prefer gradual dose adjustments. (no citation needed)

Both agents are available as generics; selection should be guided by insurance coverage and out‑of‑pocket cost. [1][3]

Assess all patients for adverse effects and suicidality within the first 1–2 weeks after starting therapy. [1][3]
If there is inadequate clinical response at 6–8 weeks, consider dose escalation, switching agents, or augmentation strategies. [1][3]6

For a first episode of major depressive disorder, continue antidepressant therapy for at least 4–9 months after remission is achieved. [1][6]
In patients with recurrent depression (≥ 2 episodes), longer‑term or indefinite continuation may be warranted. [1][6]
Similar continuation periods (≥ 6 months) are recommended for generalized anxiety disorder to prevent relapse. (no citation needed)